Intratympanic injection of Edaravone for idiopathic sudden sensorineural hearing loss

Intratympanic injection of Edaravone for idiopathic sudden sensorineural hearing loss - Intratympanic Edaravone therapy for ISSHL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008127

Enrollment

Registered

2012-06-11

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic sudden sensorineural hearing loss

Interventions

intratympanic edaravone injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) within three days from the onset 2) average hearing level >= 90dB

Exclusion criteria

Exclusion criteria: 1) patients with serious general complication 2) patients with anaphylaxis aganst edaravone 3) woman with pregnancy/lactation

Design outcomes

Primary

Measure	Time frame
five frequencies average hearing level in pure tone audiogram	—

Countries

Japan

Contacts

Public ContactHjime Sano

Kitasato University Hospital Department of Otorhinolaryngology

sanohj@med.kitasato-u.ac.jp042-778-8466

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026